Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	Aug '25 Aug 8, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2020
Market Capitalization	45,272	45,272	-	-	-	-	Upgrade
Enterprise Value	52,866	49,137	-	-	-	-	Upgrade
Last Close Price	2370.00	2370.00	4887.53	3333.94	-	-	Upgrade
PS Ratio	1.23	1.43	-	-	-	-	Upgrade
PB Ratio	1.41	1.37	-	-	-	-	Upgrade
P/TBV Ratio	1.43	1.39	-	-	-	-	Upgrade
EV/Sales Ratio	1.44	1.55	-	-	-	-	Upgrade
EV/EBITDA Ratio	20.40	24.26	-	-	-	-	Upgrade
EV/EBIT Ratio	24.37	30.82	-	-	-	-	Upgrade
Debt / Equity Ratio	0.41	0.41	0.67	0.64	0.93	1.30	Upgrade
Debt / EBITDA Ratio	5.23	6.61	5.67	2.25	5.40	17.35	Upgrade
Debt / FCF Ratio	-	-	3.45	-	3.12	-	Upgrade
Asset Turnover	0.70	0.66	0.81	0.87	0.71	0.61	Upgrade
Inventory Turnover	5.11	3.39	6.39	6.13	5.75	4.86	Upgrade
Quick Ratio	0.58	0.60	1.43	0.57	0.56	0.30	Upgrade
Current Ratio	1.17	1.23	1.81	0.97	0.88	0.74	Upgrade
Return on Equity (ROE)	-17.71%	-19.15%	11.09%	23.18%	17.41%	2.75%	Upgrade
Return on Assets (ROA)	2.49%	2.09%	3.20%	8.25%	4.30%	0.70%	Upgrade
Return on Capital (ROIC)	3.50%	2.49%	3.75%	10.26%	5.45%	0.82%	Upgrade
Return on Capital Employed (ROCE)	6.10%	4.60%	6.10%	22.60%	11.00%	1.90%	Upgrade
Earnings Yield	-9.91%	-11.24%	-	-	-	-	Upgrade
FCF Yield	-62.73%	-21.29%	-	-	-	-	Upgrade
Buyback Yield / Dilution	-27.10%	-18.87%	0.18%	-335.81%	-15.13%	0.46%	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.